我院替格瑞洛致不良反应108例分析

Analysis of 108 Cases of Adverse Drug Reactions Induced by Ticagrelor in Our Hospital

目的：探讨替格瑞洛致不良反应（ADR）的一般规律和特点,为临床合理用药提供参考。方法：随访我院2013年12月-2015年6月间使用替格瑞洛的患者672例,对其服药后的ADR情况进行分析、总结。结果：参与调查的672例患者共有78例（11.6%）发生了108例次ADR,男女比例为5.5∶1,差异有统计学意义（P〈0.05）;51~60岁患者最多（37.2%）;主要累及器官/系统为呼吸系统（41.7%）和皮肤及其附件（38.0%）,主要临床表现为轻微出血（78.7%）、呼吸困难（17.6%）和心跳减慢（2.8%）等;未发现严重的ADR。结论：替格瑞洛具有良好的安全性和耐受性,但由于其上市时间较短,且在亚洲人群中缺少大规模的临床试验的循证医学证据,临床应加强用药监测,减少ADR发生,确保用药安全。

OBJECTIVE： To explore the general regulation and characteristics of adverse drug reactions （ADR） induced by ticagrelor, and provide reference for clinical rational drug use. METHODS： 672 patients received ticagrelor in our hospital from Dec. 2013 to Jun. 2015 were followed-up, and the situation was analyzed and summarized after taking drug. RESULTS： In the 672 patients, 78 （11.6%） patients suffered from 108 cases of ADR, the ratio of male to female was 5.5：1, there was statistical significance （P〈0.05） ; patients mostly aged 51-60 years （37.2%） ; the mainly involved organs/systems were respiratory system （41.7%） , and skin and its appendages （38.0%） , the main clinical manifestations were minor bleeding （78.7%） , dyspnea （17.6%） and bradycardia （2.8%） ;no severe ADR was found. CONCLUSIONS： Ticagrelor had good safety and tolerability, but due to its shorter time to market in China and absense of evidence-based medicine for large-scale clinical trials in Asian population, clinic should strengthen medication monitoring to reduce the ADR and ensure drug safety.